metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Severe thrombocytopenia due to idiopathic myelodysplastic syndrome complicated b...
Información de la revista
Vol. 78.
(enero - diciembre 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
944
Vol. 78.
(enero - diciembre 2023)
Comments
Acceso a texto completo
Severe thrombocytopenia due to idiopathic myelodysplastic syndrome complicated by spontaneous, fatal intracerebral hemorrhage
Visitas
944
Carla Alexandra Scorzaa, Antonio-Carlos G. de Almeidab, Fulvio Alexandre Scorzaa, Josef Finstererc,
Autor para correspondencia
fifigs1@yahoo.de

Corresponding author.
a Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, SP, Brazil
b Centro de Neurociências e Saúde da Mulher “Professor Geraldo Rodrigues de Lima”, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, SP, Brazil
c Neurology & Neurophysiology Center, Vienna, Austria
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Results of blood tests shortly before the fatal bleeding.
Texto completo

Myelodysplastic Syndromes (MDSs) are a group of disorders that occur predominantly in men over the age of 65 years and are characterized by poorly formed or malfunctioning blood cells.1,2 The cause of MDSs often remains elusive, but some patients have a history of radiotherapy or chemotherapy. Common measures include blood transfusions and drugs to increase blood cell production. In certain situations, a Bone Marrow Transplant (BMT), also known as a stem cell transplant, may be recommended to replace the bone marrow with healthy bone marrow from a donor.1,2 MDSs are often complicated by the development of malignancy, infections, stroke, or bleedings due to thrombocytopenia.1,2 Although Intracerebral Bleeding (ICH) has been reported in association with MDS3, spontaneous ICH due to severe thrombocytopenia secondary to MDS has not been reported.

An 81-year-old Caucasian male, height 160 cm, weight 58 kg, was diagnosed with MDS Refractory Anemia with Excessive Blasts (RAEB) II on a bone marrow biopsy performed to work up a previously unknown pancytopenia (Table 1). A cause for MDS could not be identified. His history was positive for left middle cerebral artery ischemic stroke 30y previously with residual mild, right-sided, spastic hemiparesis and sensorimotor aphasia, well-controlled arterial hypertension, benign prostatic hyperplasia, ileus 10y earlier, and bilateral pneumonia. During two hospital stays due to constipation or pneumonia shortly before the ICH, he was treated with platelet concentrates and erythrocyte concentrates (Table 1). Severe thrombocytopenia recurred a few days after each transfusion.

Table 1.

Results of blood tests shortly before the fatal bleeding.

Parameter  RL  dbd79  dbd74  dbd71a  dbd32  dbd29  dbd27a  dbd25a  dbd4 
Erythrocytes  4.2-5-5/pL  2.8  2.53  3.46  2.8  1.87  2.65  2.79  2.11 
Hemoglobin  14‒17g/dL  8.7  8.1  10.8  8.8  5.6  8.0  8.8  6.3 
Hematocrit  40‒50%  25.2  22.8  30.6  24.4  16.8  23.4  24.2  22.1 
Thrombocytes  150‒450 nL  27  33  53  11  36  51  11 
Reticulocytes  5‒15%  18  Nd  nd  nd  nd  nd  nd  nd 
Leucocytes  4‒9 nL  2.2  1.8  2.3  2.8  1.6  2.0  1.8  1.5 
PTZ  70‒130%  61  65  nd  66  nd  66  nd  nd 
PTT  <34s  21  29  nd  27.7  nd  27.4  nd  nd 

dbd, Days before decease; nd, Not done; PTT, Partial Thromboplastin Time; PTZ, Prothrombin Time; RL, Reference Limits.

a

fter thrombocyte concentrates and erythrocyte concentrates.

Two months after diagnosis of MDS, the patient suddenly became comatose with non-reactive pupils. His blood pressure was 145/77 mmHg. Platelet count was 11 nL four days before ICH (Table 1). emergency Cerebral Computed Tomography (CCT) revealed a left, frontotemporal, intracerebral mass bleeding with ventricular rupture (Fig. 1). Neurosurgeons saw no indication for surgical rehabilitation of the bleeding.

Fig. 1.

Cerebral CT scan showing intra-axial mass bleeding with ventricular rupture in a left fronto-temporal distribution.

(0.19MB).

The patient is interesting because he is a rare case of MDS with severe thrombocytopenia complicated by spontaneous ICH. ICH was attributed to thrombocytopenia as other causes of bleeding, such as acute hypertensive crisis, coagulation disorder, venous sinus thrombosis with secondary bleeding, ischemic stroke with secondary bleeding, rupture of an aneurysm, drugs, and transformation of MDS to acute myeloid leukemia4 were ruled out. There was also no evidence of hemolysis. Thrombocytopenia has previously been identified as a risk factor for ICH5. However, low platelet counts do not necessarily lead to bleeding. There have been reports of MDS patients with thromboembolic events despite low thrombocytes.6 Thrombotic events in MDS patients with low platelet counts are most likely due to the presence of dysfunctional thrombocytes, which can lead to a susceptibility to thrombus formation. In general, the risk of thrombotic events exceeds the risk of bleeding in patients with MDS.7 Although a few patients with MDS and cerebral bleeding have been reported,3 spontaneous ICH due to thrombocytopenia is a rare event. With regard to the cause of MDS in the index patient, a comprehensive workup was not carried out due to the short period between the discovery of the pancytopenia and death, the age of the patient, and due to the lack of therapeutic consequences. Although the use of thrombocyte and erythrocyte concentrates showed a favorable effect, it was only temporary. For this reason, the use of azacitidine was considered by the oncologists.

In summary, this case demonstrates that idiopathic MDS can be complicated by spontaneous ICH in the presence of severe thrombocytopenia. Whether pathophysiological mechanisms other than thrombocytopenia contributed to the bleeding, remains speculative and requires further studies.

Declarations

Informed consent: Was obtained.

Ethics approval: The study was approved by the institutional review board.

Data availability: Not applicable.

Consent to participate: Not applicable.

Consent for publication: Not applicable.

Author contributions

JF: design, literature search, discussion, first draft, critical comments.

Funding

No funding was received.

References
[1]
AG Jain, H. Elmariah.
BMT for myelodysplastic syndrome: when and where and how.
Front Oncol, 11 (2022),
[2]
AG Jain, L Zhang, JM Bennett, R. Komrokji.
Myelodysplastic syndromes with bone marrow fibrosis: an update.
Ann Lab Med, 42 (2022), pp. 299-305
[3]
K Ohtsubo, K Takase, K Nagafuji, H Henzan, T Tanimoto, T Fukuda, et al.
Nonmyeloablative allogeneic bone marrow transplantation for treatment of myelodysplastic syndrome complicated by recent intracerebral hemorrhage.
Am J Hematol, 77 (2004), pp. 400-404
[4]
KM Scott, FP Gardner, BH Eidelman, CE Rivera, DM Menke, KM. Barrett.
Clinical reasoning: a 69-year-old man with leukocytosis and hemorrhagic brain lesions.
[5]
A González-Duarte, GS García-Ramos, SI Valdés-Ferrer, C. Cantú-Brito.
Clinical description of intracranial hemorrhage associated with bleeding disorders.
J Stroke Cerebrovasc Dis, 17 (2008), pp. 204-207
[6]
L Russell, LB Holst, L Kjeldsen, J Stensballe, A. Perner.
Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies.
Ann Intensive Care, 7 (2017), pp. 119
[7]
K Adelborg, P Corraini, B Darvalics, H Frederiksen, A Ording, E Horváth-Puhó, et al.
Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
J Thromb Haemost, 17 (2019), pp. 1305-1318
Copyright © 2023. HCFMUSP
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.clinsp.2023.100186
No mostrar más